Agios Pharmaceuticals, Inc. (AGIO) Return on equity 2016–2025
Agios Pharmaceuticals, Inc. (AGIO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-34.6%FY2025 · since FY2016: -55.3% → -34.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -34.6% | -78.4 pp |
| FY2024 | 43.7% | +87.1 pp |
| FY2023 | -43.4% | -22.3 pp |
| FY2022 | -21.1% | -145.3 pp |
| FY2021 | 124.2% | +206.2 pp |
| FY2020 | -81.9% | -17.7 pp |
| FY2019 | -64.2% | -13.9 pp |
| FY2018 | -50.3% | +33.5 pp |
| FY2017 | -83.8% | -28.5 pp |
| FY2016 | -55.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice